A synthetic peptide from internal region of human CTRP5 conjugated to an immunogenic carrier protein was used as the antigen. The antigen is homologous in rat and mouse.
IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.
Handling Advice
Avoid freeze and thaw cycles.
Storage
4 °C/-20 °C
Storage Comment
Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
Expiry Date
12 months
Target
CTRP5 (C1QTNF5)
(C1q and Tumor Necrosis Factor Related Protein 5 (C1QTNF5))
C1QTNF5 antibody, wu:fb02c10 antibody, wu:fb02f05 antibody, zgc:112378 antibody, CTRP5 antibody, Ctrp5 antibody, C1q and tumor necrosis factor related protein 5 antibody, C1q and TNF related 5 antibody, C1QTNF5 antibody, c1qtnf5 antibody, C1qtnf5 antibody
Background
Defects in C1QTNF5 are a cause of late-onset retinal degeneration (LORD). LORD is an autosomal dominant disorder characterized by onset in the fifth to sixth decade with night blindness and punctate yellow-white deposits in the retinal fundus, progressing to severe central and peripheral degeneration, with choroidal neovascularization and chorioretinal atrophy. Subcellular location: Secreted,Vision,Complement C1q tumor necrosis factor-related protein 5, C1QTNF5